LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 28 of 66
Next
>>
>
676 to 700 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Dasatinib	180619_MC_10	6539	0.0351	68	164	5	17	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_1	232	0.0343	635.9	71.1	15071	356.7	0.0231	0.01119	0.6658
Dasatinib	180619_MC_10	5808	0.0366	67	148	6	6	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_2	215	0.0357	635.9	71.1	15071	356.7	0.0231	0.01262	0.6231
Dasatinib	180619_MC_10	6606	0.0233	56	99	6	16	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_3	155	0.0229	635.9	71.1	15071	356.7	0.0231	-0.00015	0.6695
Dasatinib	180619_MC_11	6318	0.0366	78	156	3	16	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_4	234	0.0357	635.9	71.1	15071	356.7	0.0231	0.01264	0.6533
Dasatinib	180619_MC_11	6830	0.0356	71	175	5	11	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_5	246	0.0348	635.9	71.1	15071	356.7	0.0231	0.01169	0.6818
Dasatinib	180619_MC_11	6191	0.0325	86	118	10	6	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_6	204	0.0319	635.9	71.1	15071	356.7	0.0231	0.00883	0.6460
Dasatinib	180619_MC_12	6829	0.0315	94	124	4	4	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_7	218	0.0309	635.9	71.1	15071	356.7	0.0231	0.00786	0.6817
Dasatinib	180619_MC_12	7725	0.0337	104	160	6	3	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_8	264	0.0330	635.9	71.1	15071	356.7	0.0231	0.00997	0.7277
Dasatinib	180619_MC_12	7754	0.0301	97	139	12	8	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_9	236	0.0295	635.9	71.1	15071	356.7	0.0231	0.00646	0.7291
Dasatinib	180619_MC_10	2269	0.1002	66	168	8	14	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_1	234	0.0935	635.9	71.1	15071	356.7	0.0231	0.07041	0.3212
Dasatinib	180619_MC_10	2087	0.0965	69	139	10	20	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_2	208	0.0906	635.9	71.1	15071	356.7	0.0231	0.06756	0.2972
Dasatinib	180619_MC_10	2301	0.0734	43	129	12	12	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_3	172	0.0696	635.9	71.1	15071	356.7	0.0231	0.04648	0.3253
Dasatinib	180619_MC_11	2409	0.0720	77	102	4	20	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_4	179	0.0692	635.9	71.1	15071	356.7	0.0231	0.04609	0.3386
Dasatinib	180619_MC_11	2212	0.1112	108	150	9	17	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_5	258	0.1045	635.9	71.1	15071	356.7	0.0231	0.08138	0.3139
Dasatinib	180619_MC_11	2449	0.0947	64	174	12	9	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_6	238	0.0886	635.9	71.1	15071	356.7	0.0231	0.06550	0.3435
Dasatinib	180619_MC_12	2680	0.1092	140	168	3	5	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_7	308	0.1031	635.9	71.1	15071	356.7	0.0231	0.08000	0.3703
Dasatinib	180619_MC_12	2248	0.1323	155	163	7	4	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_8	318	0.1239	635.9	71.1	15071	356.7	0.0231	0.10085	0.3185
Dasatinib	180619_MC_12	3008	0.0704	87	131	14	17	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_9	218	0.0676	635.9	71.1	15071	356.7	0.0231	0.04450	0.4053
Dasatinib	180619_MC_10	1604	0.1423	61	176	3	22	Dasatinib	0.997999808	treatment	72	2	MCF10A-GM_1	237	0.1287	635.9	71.1	15071	356.7	0.0231	0.10566	0.2246
Dasatinib	180619_MC_10	1575	0.1408	51	178	4	12	Dasatinib	0.997999808	treatment	72	2	MCF10A-GM_2	229	0.1269	635.9	71.1	15071	356.7	0.0231	0.10387	0.2197
Dasatinib	180619_MC_10	1448	0.1064	46	113	11	3	Dasatinib	0.997999808	treatment	72	2	MCF10A-GM_3	159	0.0989	635.9	71.1	15071	356.7	0.0231	0.07587	0.1975
Dasatinib	180619_MC_11	1770	0.1450	57	208	6	12	Dasatinib	0.997999808	treatment	72	2	MCF10A-GM_4	265	0.1302	635.9	71.1	15071	356.7	0.0231	0.10715	0.2513
Dasatinib	180619_MC_11	1447	0.1699	95	167	7	11	Dasatinib	0.997999808	treatment	72	2	MCF10A-GM_5	262	0.1533	635.9	71.1	15071	356.7	0.0231	0.13023	0.1973
Dasatinib	180619_MC_11	1786	0.1381	61	194	12	13	Dasatinib	0.997999808	treatment	72	2	MCF10A-GM_6	255	0.1249	635.9	71.1	15071	356.7	0.0231	0.10186	0.2537
Dasatinib	180619_MC_12	1460	0.1430	106	118	8	19	Dasatinib	0.997999808	treatment	72	2	MCF10A-GM_7	224	0.1330	635.9	71.1	15071	356.7	0.0231	0.10994	0.1996

|<
<<
Previous
Page 28 of 66
Next
>>
>
676 to 700 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)